Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
4 search results for:

Axicabtagene ciloleucel 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 10-12-2018 | B-cell lymphoma | News | Article

    Long-term data further support axicabtagene ciloleucel use for refractory large B-cell lymphoma

    The 2-year follow-up results from the phase I/II ZUMA-1 trial of patients with refractory large B-cell lymphoma show that the chimeric antigen receptor T-cell therapy axicabtagene ciloleucel remains efficacious and manageable in the long term.

    Published in:
    Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30864-7 ASH 2018; San Diego, California, USA; 1–4 December
  2. 19-10-2017 | CAR T-cell immunotherapy | News | Article
    approvalsWatch

    Second CAR T-cell therapy receives FDA approval

    medwireNews : The US FDA has granted approval for use of the chimeric antigen receptor (CAR) T-cell immunotherapy axicabtagene ciloleucel in adults with some forms of non-Hodgkin lymphoma.

  3. 22-12-2017 | B-cell lymphoma | News | Article

    CAR T-cell therapy effective for refractory large B-cell lymphomas

    The personalized CAR T-cell product axicabtagene ciloleucel (axi-cel) was successfully manufactured and delivered at a target dose of 2x10 6  cells/kg to 101 (91%) participants after administration of a conditioning regimen comprising low-dose cyclophosphamide and fludarabine.

    Published in:
    N Engl J Med 2017; Advance online publication, ASH 2017; Atlanta, Georgia, USA
  4. 16-07-2018 | EMA | News | Article
    approvalsWatch

    EMA recommends two CAR T-cell therapies for approval

    medwireNews : Marketing authorizations have been recommended by the EMA for use of the chimeric antigen receptors (CAR) T-cell therapies tisagenlecleucel and axicabtagene ciloleucel for the treatment of specific blood cancers.

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.